Topping the list of November alliances was a potential $4.5bn deal between Arcturus Therapeutics Ltd. and CSL Seqirus.
Under the agreement, Arcturus will provide CSL Seqirus with a license to its self-amplifying mRNA technology to support the research,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?